Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes : ESMO Clinical Practice Guideline
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Annals of oncology : official journal of the European Society for Medical Oncology - 34(2023), 1 vom: 01. Jan., Seite 33-47 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sessa, C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BRCA |
|---|
| Anmerkungen: |
Date Completed 03.01.2023 Date Revised 16.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.annonc.2022.10.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34821376X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34821376X | ||
| 003 | DE-627 | ||
| 005 | 20231226035643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2022.10.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1160.xml |
| 035 | |a (DE-627)NLM34821376X | ||
| 035 | |a (NLM)36307055 | ||
| 035 | |a (PII)S0923-7534(22)04193-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sessa, C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes |b ESMO Clinical Practice Guideline |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.01.2023 | ||
| 500 | |a Date Revised 16.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BRCA | |
| 650 | 4 | |a ESMO Clinical Practice Guideline | |
| 650 | 4 | |a hereditary breast and ovarian cancer syndromes | |
| 650 | 4 | |a risk reduction | |
| 700 | 1 | |a Balmaña, J |e verfasserin |4 aut | |
| 700 | 1 | |a Bober, S L |e verfasserin |4 aut | |
| 700 | 1 | |a Cardoso, M J |e verfasserin |4 aut | |
| 700 | 1 | |a Colombo, N |e verfasserin |4 aut | |
| 700 | 1 | |a Curigliano, G |e verfasserin |4 aut | |
| 700 | 1 | |a Domchek, S M |e verfasserin |4 aut | |
| 700 | 1 | |a Evans, D G |e verfasserin |4 aut | |
| 700 | 1 | |a Fischerova, D |e verfasserin |4 aut | |
| 700 | 1 | |a Harbeck, N |e verfasserin |4 aut | |
| 700 | 1 | |a Kuhl, C |e verfasserin |4 aut | |
| 700 | 1 | |a Lemley, B |e verfasserin |4 aut | |
| 700 | 1 | |a Levy-Lahad, E |e verfasserin |4 aut | |
| 700 | 1 | |a Lambertini, M |e verfasserin |4 aut | |
| 700 | 1 | |a Ledermann, J A |e verfasserin |4 aut | |
| 700 | 1 | |a Loibl, S |e verfasserin |4 aut | |
| 700 | 1 | |a Phillips, K-A |e verfasserin |4 aut | |
| 700 | 1 | |a Paluch-Shimon, S |e verfasserin |4 aut | |
| 700 | 0 | |a ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology : official journal of the European Society for Medical Oncology |d 1990 |g 34(2023), 1 vom: 01. Jan., Seite 33-47 |w (DE-627)NLM012606308 |x 1569-8041 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2023 |g number:1 |g day:01 |g month:01 |g pages:33-47 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.annonc.2022.10.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2023 |e 1 |b 01 |c 01 |h 33-47 | ||